1 Aminoglutethimide (AG) 500 mg was administered orally to four normal volunteers and eight patients undergoing treatment for metastatic breast cancer. In each subject the acetylator phenotype was established from the monoacetyldapsone (MADDS)/dapsone (DDS) ratio. 2 Acetylaminoglutethimide (acetylAG) rapidly appeared in the plasma and its disposition paralleled that of AG. 3 A close relationship (P < 0.01) was observed between the acetyl AG/AG and MADDS/DDS ratio suggesting that AG may undergo polymorphic acetylation like DDS. 4 AG half-life was 19.5 + 7.7 h in seven fast acetylators of DDS and 12.6 + 2.3 h in five slow acetylators and its apparent metabolic clearance was significantly (P < 0.01) related to the acetylAG/AG ratio. 5 Over 48 h the fast acetylators excreted 7.7 + 4.4% of the administered AG dose in the urine as unchanged AG as compared to 12.4 + 2.8% in slow acetylators. A much smaller fraction of the dose was excreted as acetylAG: 3.6 + 1.5% by fast and 1.9 ± 1.0% by slow acetylators respectively. 6 After 7 days treatment with AG at an accepted clinical dose regimen to the eight patients there were significant reductions in the half-lives of AG (P < 0.01) and acetylAG (P < 0.01) and a trend (0.1 > P > 0.05) towards reduction of the acetylAG/ AG ratio which became significant (P < 0.05) if the one patient on a known enzyme inducer was omitted. The mean apparent volume of distribution was not significantly (P > 0.1) altered but the mean apparent systemic clearance of AG was increased (P < 0.05). These changes are attributed to auto-induction of oxidative enzymes involved in AG metabolism.
Introduction
Aminoglutethimide, AG, [3-(4-aminophenyl)-aromatisation of adrenal androgens (Santen et 3-ethyl-piperidine-2,6-dionel is being used in-al., 1982b) . When given with replacement creasingly for the palliative endocrine therapy hydrocortisone, AG blocks oestrogen synthesis of metastatic breast carcinoma in post-meno-in the adrenal cortex, in extraglandular pausal women (Santen et al., 1982a) . It inhibits peripheral tissues containing aromatase and in both adrenal steroid synthesis (Cash et al., the breast carcinoma itself. 1967; Fishman et al., 1967) effects, details of its metabolism remain obscure. Older studies (Douglas & Nicholls, 1972) have indicated that N-acetylation to acetamidoglutethimide (acetylAG) is a major (4-25%) pathway and more recent studies suggested that this acetylation is polymorphic (Coombes et al., 1982) . Other metabolites that have been demonstrated are N-formyl-aminoglutethimide, nitroglutethimide and N-hydroxylaminoglutethimide (Baker et al., 1981) . However, little information exists relating the acetylation phenotype to the pharmacokinetics of aminoglutethimide (AG) and acetamidoglutethimide (acetylAG). Furthermore, repeated doses of AG result in autoinduction (Murray et al., 1979) and the influence of this process upon the pharmacokinetics of the drug has not been studied.
In this paper we report studies relating the pharmacokinetics of AG to acetylator phenotype and autoinduction.
Methods

Subjects
After approval by the Ethics Committee of Guy's Hospital, four healthy volunteers agreed to participate in the study. Eight patients with progressive metastatic breast carcinoma after prior endocrine therapy (ovarian ablation or tamoxifen) in the Breast Unit, Guy's Hospital, who were about to start treatment with aminoglutethimide gave informed consent to participate in the study. Details of these subjects appear in Table 1 . All the normal volunteers and patients had normal haematological indices and clinical chemistry except for patient PM who had hypercalcaemia.
Acetylator phenotyping
The acetylator phenotype was determined according to the criteria of Gelber et al. (1971) using the ratio of monoacetyldapsone (MADDS) to dapsone (DDS) concentrations in plasma at 2-4 h following oral administration of 100 mg DDS. Plasma DDS and MADDS concentrations were assayed by a modification of the high performance liquid chromatographic method of Carr et al. (1978) .
Pharmacokinetic study of aminoglutethimide AG 500 mg was administered in a gelatin capsule; this was the first treatment dose in the patients with breast cancer. All subjects were given this dose except patient MF (Table 1) who received 375 mg also in a gelatin capsule due to her low body weight of 42 kg. Each received the AG capsule with 200 ml water after an overnight fast. No alcohol or smoking was allowed during the pharmacokinetic sampling. It was thought unethical to stop other therapies which the patients was receiving (Table 1) . None of these drugs was polymorphically acetylated nor were they known microsomal enzyme inducers (except in the case of patient MF who was receiving chronic treatment with phenytoin). Food was given 4 h after drug administration. Venous blood samples were taken before dosing and at 0.5, 1, 1.5, 2, 3, 4, 5, 6, 9, 12, 15, 24, 30 and 48 h in the volunteers and at 2,4, 6, 9, 12, 15, 24, 30 and 48 h in the patients. Blood was taken into lithium heparin tubes via an indwelling cannula fitted with a heparin lock. The plasma was immediately separated and stored at -20°C pending analysis. Two total urine collections were made over 0-24 h and 24-48 h in each subject. The volumes were noted and aliquots were stored at -200C.
After completion of this sampling schedule, each patient but not the normal subjects, recieved AG 250 mg 12 hourly as Orimeten (Ciba-Geigy) tablets plus hydrocortisone 20 mg 12 hourly. After 1 week of therapy AG was stopped for a 48 h 'washout' period and the plasma and urine samples taken as described above following the same single dose of AG 500 mg in a gelatin capsule. During this second phase, replacement therapy with hydrocortisone was continued.
Drug analysis AG and acetylAG were simultaneously estimated in plasma and urine by high performance reverse phase liquid chromatography. In brief, 0.5 ml plasma or urine was mixed with 15 ,u of a solution of 100 ,ug/ml phenacetin in methanol (internal standard) and 0.5 ml pH 6 acetate buffer and then extracted with 3 ml dichloromethane for 10 min. After centrifugation the organic phase was transferred to a clean dry tube and evaporated to dryness in a stream of dry nitrogen at 400C. The residue was taken up in 250 ,ul of solvent system (methanol/water v/v 42:58) and 50 RI injected into the chromatograph. The solvent was delivered at 1 ml/min to a 25 cm x 4.6 mm ,u Bondapak C18 column of 10 pm particle size (Waters Associates, (Baker et al., 1981; Coombes et al., 1982) . The interassay coefficients of variation (n = 6) for AG in plasma ranged from 14.3% at 1 pLg/ml to 6.9% at 8 ,ug/ml and in urine from 3.7% at 10 ,ug/ml to 1.9% at 160 S.g/ml. For acetylAG the interassay coefficients of variation were in plasma 8.3% at 0.5 pug/ml and 4.8% at 4 ,ug/ml and in urine 4.5% at 5 ,ug/ml and 0.8% at 80 pg/ml.
Reagents
All solvents were Analar grade and were used as purchased from BDH Chemicals Ltd (Poole, Dorset).
We are grateful to Dr M. Jarman (Royal Marsden Hospital, Sutton) and Professor P. J. Nicholls (Welsh School of Pharmacy, Cardiff) for kind gifts of acetylAG and to Dr V. A. John of Ciba-Geigy Ltd (Horsham, Sussex) for the gift of pure AG.
Data analysis
The terminal elimination rate constant (Xi) was determined by least squares fitting of ln (plasma concentration) on time from which t½, = 0.693/ X,. Areas under the plasma concentration vs time curve (AUC) were estimated by the linear trapezoidal rule with appropriate extrapolation to infinite time. No intravenous form of AG is available and there is presently no formal estimate of the bioavailability fraction (F) of. this drug available. However, on the basis of the elimination of radioactivity following oral administration of radio-labelled AG, Dalrymple & Nicholls (1984) have suggested that the bioavailability of the drug from solution is essentially complete and that this is likely also to apply to solid formulations of the drug. Apparent systemic clearances (CL) and apparent volumes of distribution (V) can be determined assuming (To convert concentration to ,umol/l, multiply by 4.268 for AG and 3.619 for acetylAG.)
The distribution of the variates consideied in this investigation are unknown. Therefore nonparametric statistical methods were used throughout: Spearman rank correlation, MannWhitney U test for two independent samples, and Wilcoxon matched pairs signed ranks test for two related samples. Regression lines were fitted by the non-parametric method of Brown and Mood (Daniel, 1978) .
Results
Absorption of AG was rapid following oral administration (Figures 1 and 2 ) although the sampling schedule adopted did not allow determination of absorption rate constants. Acetyl-AG was rapidly generated from AG and its disposition profile paralleled that of AG closely. AG acetylation ratio (r, = -0.715; P < 0.01).
Thus lower acetylation ratios ('slow acetylation') were associated with higher clearances and shorter half-lives. A similar result was obtained using plasma AUC determined over the 48 h sampling period, rather than extrapolation to infinite time. This indicates the relatively small contribution of the infinite correction term to overall AUC.
The percentage of the AG dose excreted in the urine as AG and acetylAG over 48 h after a single dose of AG in fast and slow DDS Figure 3 . Slow DDS acetylators excreted significantly (P < 0.05) less acetylAG than fast acetylators. In absolute terms, however, the excretion of this metabolite was low. A greater quantity of AG was excreted in the urine over 48 h and this was significantly (P < 0.05) higher in slow DDS acetylators. These differences became less obvious after 1 week's treatment with AG (Table 5) . The effect of a 1 week treatment with AG was studied in eight patients and the resulting changes in pharmacokinetic parameters are shown in Tables 4 and 5 . In six patients the AG acetylation ratio was decreased (Table 4 cf. Acetylation and aminoglutethimide 501 received phenytoin for over 1 year and thus might be expected to be maximally induced: it will be noted from Table 3 that she had the shortest AG half-life amongst the fast DDS acetylators. This patient, however, shared in the significantly (P < 0.05) increased mean apparent metabolic clearance of AG following AG treatment for 1 week. There were significant (P < 0.01) reductions in the mean halflives of both AG and acetylAG and these were accompanied by increased apparent systemic clearances in all patients except PM (Table 5 cf. Table 3 ). Following induction, the relationship between the AG acetylation ratio and half-life remained. There were significant relationships between this ratio and both half-life (r. = 0.90; P < 0.01) and apparent metabolic clearance (r, = -0.74; P < 0.05). No significant (P > 0.1) change occurred in mean apparent volume of distribution after AG treatment. Two previous studies (Murray et al., 1979; Thompson et al., 1981) have investigated the pharmacokinetics of AG using a non-specific spectrophotometric assay. Despite reservations concerning their analytical methods, the pharmacokinetic parameters for AG found in these studies are comparable with those using the high performance liquid chromatographic procedure presented here. The half-lives (for six subjects in both studies) were 13.3 ± 2.7 h (Murray et al., 1979) and 12.5 ± 1.6 h (Thompson et al., 1981) . The total body clearances were more variable, however, being 43 ± 6 ml min-' (Murray et al., 1979) and 86.2 + 5.6 ml min-1 (Thompson et al., 1981) (1980) , no definitive study has been made of the pharmacokinetics of this compound in man. The presence of the amine function in AG confers upon the molecule its ability to inhibit cholesterol side chain cleavage and aromatase since this is absent in glutethimide which has no antisteroidogenic activity . Acetylation at this site might therefore be anticipated to reduce the therapeutic effects of AG. In vitro studies on steroid synthesis by adrenal cell monolayer cultures showed that whilst 10 ,ug ml-' AG inhibited steroid output by more than 90%, the same concentration of acetylAG reduced it by 42% (Coombes et al., 1980) . Foster et al. (1983) , however, found acetylAG to be devoid of inhibitory activity on the desmolase from bovine adrenal cortex at a concentration of 50 ,ug/ml and on the aromatase of human placenta at a concentration of 20 ,ug/ml. Clinical experience shows acute side effects of AG administration: lethargy, orthostatic dizziness, ataxia, fever and rashes to be common (up to 43% of patients) but to resolve on chronic treatment (Santen et al., 1982a ) possibly due to enzyme induction (Murray et al., 1979) . The sedative and central nervous system depressant actions of AG are most probably related to its structural affinity with glutethimide, barbiturates and thalidomide. No data are available concerning possible central sedative properties of acetylAG in man although it has equal antileptazol activity to AG in mice and is reported to be ten times less sedative in that species (Douglas & Nicholls, 1972) . The parallelism of AG and acetylAG elimination rates suggests that formation of this metabolite is rate limiting and the first order rate constant for metabolite formation is either greater than or identical with that for AG elimination.
AG markedly accelerates the metabolism of dexamethasone (after only 2 weeks' treatment, its clearance is increased by almost 300%) but has no effect on cortisol, oestrone, ndrostenedione or medroxyprogesterone acetate clearances (Santen et al., 1982b 2 days of starting medication (Jackson et al., 1978) : it is not certain that AG induction was complete after a single week of treatment. Jarman et al. (1983) Douglas & Nicholls (1972) found it to be the major urinary metabolite in man accounting for 4-25% of the administered dose after a single dose of AG. N-acetylation of many drugs shows genetic polymorphism with fast and slow acetylation phenotypes although this process is not invariably polymorphic. There is no evidence that it is inducible. Coombes et al. (1982) showed that in subjects acetylator-phenotyped into fast and slow acetylators using sulphadimidine, the slow acetylators excreted more AG (mean 28% in 24 h) of a single dose than did fast acetylators (12%) but the latter excreted more acetylAG (8.8%) than the former (3.9%). These observations have thus been confirmed by the present study. The urinary excretion of AG and acetyl-AG found in the present study is lower than that reported using non-specific colorimetric assay (Douglas & Nicholls, 1972) which found elimination of 34-50 and 4-25% of the dose as AG and acetylAG respectively in 48 h. However, Coombes et al. (1982) , using high performance liquid chromatography show a wide range of values, those for AG being 0.6-36.5% in 24 h and for acetylAG 2.7-12% in 24 h in a group of fast and slow acetylators. The relationship between DDS acetylation phenotype and these observations permit the tentative conclusion that AG is a drug which demonstrates polymorphic acetylation in man. We have been unable to confirm (see Figures 1 and 2 ) the preliminary observation by Coombes et al. (1980) that the plasma concentrations of acetyl-AG are higher than the AG concentrations in rapid acetylators. They only studied nine subjects at three time points, however, and although in general the mean acetylAG/AG ratio is higher in their fast acetylators than in the slow acetylators, its value is variable. We have found this ratio to be altered by induction but it probably remains constant within an individual over a single dose interval.
The concept of fast and slow acetylators may be easily applied to drugs in which acetylation is a major pathway for disposition and for which it determines half-life and clearance, e.g. isoniazid (Weber & Hein, 1979) , sulphamethazine (Evans & White, 1964) , hydralazine (Reece et al., 1980) . For DDS, acetylation is a minor elimination pathway and although the ratio of MADDS to DDS accurately reflects acetylator phenotype, the half-life is similar in fast and slow acetylators (Gelber et al., 1971 ). In the case of AG, our observations are at first sight paradoxical: fast acetylators, although they have a higher acetylAG/AG ratio have a longer half-life and lower clearance for AG than slow acetylators. This paradox has not been previously noted with other drugs but possibly occurs with phenelzine. Caddy et al. (1978) , on the basis of urinary excretion, found that the half-life of phenelzine in three slow acetylators was shorter (0.40, 0.58 and 0.72 h) than in two fast acetylators (1.03 and 1.61 h). The vasodilator endralazine was required in slightly (but not significantly) lower dosage to produce a given fall in blood pressure in 34 slow acetylators as compared to 16 fast acetylators (Holmes et al., 1983) . Although fast acetylators form higher concentrations of acetylated endralazine in the plasma than slow acetylators, no significant difference in endralazine half-life has been found between acetylator phenotypes (Reece et al., 1982; Meredith et al., 1983) . Like AG, endralazine does not have acetylation as a major elimination route.
An explanation of these observations is not presently forthcoming, particularly since the overall metabolic fate of AG in man is not completely known. Some form of product inhibition is a possibility, although this would have to be one of regulation of an oxidative pathway(s) by acetyl metabolites). Coombes et al. (1982) showed that slow acetylators excreted more nitroglutethimide in the urine than fast acetylators but since even in the former this constituted only 0.1% of the dose, it is unlikely to make a major contribution to AG disposition. Deacetylation of mono-and diacetyldapsone has been documented in man (Gelber et al., 1971) and in the case of that drug rapidly achieves equilibrium. Possibly acetylAG acts as a reservoir (akin to protein binding) for drugs eventually eliminated by oxidative mechanisms. The solution clearly awaits further investigations to clarify the metabolism of AG which will require the administration of acetylAG as sole agent.
